Clinical trial · Observational
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
The Effectiveness and Safety of Different Treatment Modalities in Real-World Clinical Practice Among Chinese Patients with Marginal Zone Lymphoma: a Prospective, Observational, Multi-center Study
NCT06534463CI-TRIAL-00083254MOTIVErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Marginal Zone Lymphoma | Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational Cohort
- description
- Including newly diagnosed marginal zone lymphoma (MZL) and relapse/refractory MZL participants who meet the treatment indications for MZL and are about to undergo MZL treatment.
- interventionNames
- Other: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- Baseline up to data cut-off (up to approximately 60 months)
- description
- Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
Secondary outcomes (7)
- measure
- Overall Response Rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * Be diagnosed as MZL * Meet the treatment indications for MZL Exclusion Criteria: * Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.